1. Home
  2. ICCC vs XGN Comparison

ICCC vs XGN Comparison

Compare ICCC & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ImmuCell Corporation

ICCC

ImmuCell Corporation

SELL

Current Price

$10.32

Market Cap

93.1M

Sector

Health Care

ML Signal

SELL

Logo Exagen Inc.

XGN

Exagen Inc.

HOLD

Current Price

$7.60

Market Cap

110.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ICCC
XGN
Founded
1982
2002
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical Specialities
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
93.1M
110.7M
IPO Year
1995
2014

Fundamental Metrics

Financial Performance
Metric
ICCC
XGN
Price
$10.32
$7.60
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
★ $10.57
AVG Volume (30 Days)
6.2K
★ 325.4K
Earning Date
11-12-2026
11-10-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 53.85
N/A
EPS
★ 0.41
N/A
Revenue
★ $26,493,169.00
N/A
Revenue This Year
N/A
$11.02
Revenue Next Year
N/A
$10.28
P/E Ratio
$25.29
★ N/A
Revenue Growth
★ 51.64
N/A
52 Week Low
$4.52
$2.59
52 Week High
$12.10
$10.41

Technical Indicators

Market Signals
Indicator
ICCC
XGN
Relative Strength Index (RSI) 52.11 56.91
Support Level $9.45 $7.81
Resistance Level $10.76 $8.94
Average True Range (ATR) 0.22 0.53
MACD -0.02 0.06
Stochastic Oscillator 48.80 79.78

Price Performance

Historical Comparison
ICCC
XGN

About ICCC ImmuCell Corporation

ImmuCell Corp is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. Its product, First Defense, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components. First Defense is designed to provide Immediate Immunity through orally delivered antibodies against the principal viral and bacterial causes of neonatal calf diarrhea (scours), including Escherichia coli (E.coli), bovine coronavirus, and bovine rotavirus. It has two operating segments: Scours and Mastitis. It derives the majority of the revenue from the Scours segment that consists of the First Defense product line.

About XGN Exagen Inc.

Exagen Inc is a medical technology company focused on the design, development and commercialization of diagnostic testing products under its AVISE brand. These products are used for the differential diagnosis, prognosis, and monitoring of rheumatic, autoimmune, and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company operates in one operating segment. The majority of the company's revenue is derived from sales of its testing products.

Share on Social Networks: